Boules Mena, Shimizu Hideharu, Zelisko Andrea, El-Hayek Kevin, Rizk Maged K, Kroh Matthew
Digestive Disease Institute, Cleveland Clinic, 9500 Euclid Avenue, A100, Cleveland, OH, 44195, USA,
Surg Endosc. 2015 Apr;29(4):805-9. doi: 10.1007/s00464-014-3754-9. Epub 2014 Aug 13.
Gastroparesis is a common chronic and costly disorder for which medical therapy is often unsuccessful. Gastric electrical stimulation (GES) has been used to treat refractory cases, however, response is variable and difficult to predict. This study aims to assess whether pre-operative opioid analgesics (OA) use affects clinical success of GES.
Records of 128 patients who underwent laparoscopic GES placement from March 2001 to September 2012 were analyzed retrospectively. Data collected included demographics, surgical outcomes, and clinical parameters. Pre- and post-operative opioid analgesic dosing (No = 0 morphine equivalents (ME)/day, Low = 0-40 ME/day, Mid = 41-80 ME/day, High >80 ME/day), as well as clinical symptom assessment was collected for up to 3 years post-operatively. Clinical success was defined as (1) OA reduction of >50 %, (2) maintenance of weight, or (3) symptom improvement. Descriptive statistics were computed for all factors. A p < 0.05 was considered statistically significant.
Fifty-three patients were on OA pre-operatively compared to 69 patients who were not. Patients not on OA pre-operatively were less likely than those on OA pre-op group to be on OA post-operatively (p = 0.005); however, there were no differences in weight or symptom improvement. Sub-group analysis of the 53 patients on OA demonstrated significant improvement in clinical symptoms in the low-morphine cohort compared to the mid-morphine cohort (p = 0.02), and OA dosing post-operatively in the low-morphine cohort diminished significantly compared to mid- and high-morphine cohort (p = 0.032). There was no significant difference in weight.
OA dosing pre-operatively significantly affects clinical success of GES placement. Criteria for offering GES implantation may need to take OA dosing into consideration.
胃轻瘫是一种常见的慢性且代价高昂的疾病,药物治疗往往效果不佳。胃电刺激(GES)已被用于治疗难治性病例,然而,反应存在差异且难以预测。本研究旨在评估术前使用阿片类镇痛药(OA)是否会影响GES的临床疗效。
回顾性分析2001年3月至2012年9月期间接受腹腔镜GES植入术的128例患者的记录。收集的数据包括人口统计学资料、手术结果和临床参数。收集术前和术后阿片类镇痛药的剂量(无=0吗啡当量(ME)/天,低=0 - 40 ME/天,中=41 - 80 ME/天,高>80 ME/天),以及术后长达3年的临床症状评估。临床成功定义为:(1)OA减少>50%,(2)体重维持,或(3)症状改善。计算所有因素的描述性统计量。p < 0.05被认为具有统计学意义。
术前使用OA的患者有53例,未使用OA的患者有69例。术前未使用OA的患者术后使用OA的可能性低于术前使用OA的患者(p = 0.005);然而,体重或症状改善方面没有差异。对53例使用OA的患者进行亚组分析显示,低吗啡组的临床症状改善程度明显高于中吗啡组(p = 0.02),且低吗啡组术后的OA剂量与中、高吗啡组相比显著减少(p = 0.032)。体重方面无显著差异。
术前OA剂量显著影响GES植入的临床疗效。提供GES植入的标准可能需要考虑OA剂量。